Claims for Patent: 12,403,126

Summary for Patent: 12,403,126

Title:	Anesthetic composition and method of anesthetizing the eye
Abstract:	A topical ophthalmic anesthetic composition includes a formulation with an amount of articaine to provide anesthetic properties when applied topically to the eye, and a pH, viscosity, osmolality, dissociation constant, and additives such as antioxidants, buffers, methylcellulose, to achieve efficacy and safety. The composition can contain articaine in amounts of about 4.0% w/v to about 12.0% w/v and have a pH of about pH 3.5 to pH 7.0. The buffer can be borate/mannitol complex obtained from boric acid or salt thereof and D-mannitol. The articaine formulations can achieve adequate anesthesia of the internal aspect of the eye wall by topical application, without the use of an injectable anesthetic. Exemplary implementations of the disclosure include formulations include articaine in an amount of at least 7.0% w/v, where the formulation is an aqueous solution, a gel, an ointment, or in an encapsulated form.
Inventor(s):	Martin Uram
Assignee:	Individual
Application Number:	US18/488,324
Patent Claims:	1. An aqueous topical ophthalmic anesthetic composition comprising: articaine in an amount of up to about 13.0% w/v based on the volume of the composition; and said composition having a pH of about pH 3.5 to about pH 7.0 to stabilize articaine and to inhibit degradation of said articaine during storage, where said composition has an osmolality of 275 to 1171 mOsm/kg to facilitate topical application for ophthalmic anesthesia. 2. The composition of claim 1, wherein said composition has a pH of about pH 4.5 to about pH 5.5, and where said buffer comprises a complex obtained from a citrate, acetate or mixture thereof and a sugar alcohol selected from the group consisting of mannitol, sorbitol and mixtures thereof. 3. The composition of claim 1, wherein said composition comprises at least about 7.5% w/v articaine and said composition has a pH of about pH 4.5 to about pH 5.0. 4. The composition of claim 1, wherein said composition contains at least about 7.0% w/v articaine and has a pH of about pH 4.5 to about pH 5.0. 5. The composition of claim 1, further comprising a borate/mannitol complex obtained from a borate and D-mannitol. 6. The composition of claim 5, wherein said borate/mannitol complex is included in an amount of about 0.5% w/v to about 0.75% w/v based on the volume of the composition. 7. The composition of claim 5, wherein said borate/mannitol complex is included in an amount of about 6.5 parts by weight to about 7.5 parts by weight based on 100 parts by weight of articaine in the composition. 8. The composition of claim 5, wherein said borate/mannitol complex is obtained from a borate/mannitol ratio of about 1:3 to about 1:7 by weight. 9. The composition of claim 1, wherein said composition comprises at least about 7.0% w/v articaine and said buffer comprises a complex of boric acid and D-mannitol in an amount to provide a pH of about pH 4.5 to about pH 5.0 and said composition further comprises sodium acetate, acetic acid, and disodium edetate. 10. The composition of claim 5, wherein said articaine is present in an amount of at least about 7.0% w/v, and said boric acid and D-mannitol complex is obtained from about 0.08% w/v to about 0.10% w/v boric acid and about 0.50% w/v to about 0.6% w/v D-mannitol based on the total volume of the composition. 11. The composition of claim 1, wherein said composition comprises at least about 8.0% w/v articaine, a buffer complex obtained from about 0.08% w/v to about 0.10% w/v boric acid and about 0.5% w/v to about 0.60% w/v D-mannitol, about 0.3 to 0.36% w/v sodium acetate, about 0.05% w/v to about 0.07% w/v disodium edetate, and the balance water, and where said composition has an osmolality of about 280 to 320 mOsm/kg and the amounts are based on the total volume of the composition. 12. An aqueous topical ophthalmic anesthetic composition comprising: articaine in an amount of about 4.0% to about 13% w/v based on the volume of the composition; said composition having a pH of pH 3.5 to 7.0 to inhibit irritation to an ocular surface and to stabilize and inhibit degradation of said articaine during storage, and maintain said articaine in solution or suspension, and where composition has an osmolality of 500 to 700 mOsm/kg. 13. The aqueous ophthalmic anesthetic composition of claim 12, said composition further comprising a borate/mannitol complex in an amount of about 6.5 parts by weight to about 7.5 parts by weight based on 100 parts by weight of articaine in the composition. 14. The aqueous ophthalmic anesthetic composition of claim 13, wherein said borate/mannitol complex is obtained from a borate/mannitol ratio of about 1:3 to about 1:7 by weight. 15. The aqueous ophthalmic anesthetic composition of claim 13, further comprising sodium diacetate, acetic acid, and disodium edetate. 16. The composition of claim 13, wherein said composition has a pH of 4.5 to 7.0. 17. The composition of claim 15, wherein said composition contains 7.5% to 8.8% w/v articaine. 18. The composition of claim 15, wherein said composition has an osmolality of 580 to 630 mOsms/kg. 19. A method of anesthetizing a surface of the eye comprising: topically administering an effective amount of a topical anesthetic aqueous composition comprising to the surface of the eye, said topical anesthetic aqueous composition comprising articaine in an amount of up to about 13.0% w/v based on the volume of the composition; and said composition having a pH of about pH 3.5 to about pH 7.0 to stabilize articaine and to inhibit degradation of said articaine during storage, where said composition has an osmolality of 275 to 1171 mOsm/kg to facilitate topical application for ophthalmic anesthesia.